Increased Urine IgM and IgG(2) Levels, Indicating Decreased Glomerular Size Selectivity, Are Not Affected by Dalteparin Therapy in Patients with Type 2 Diabetes.
Author
Summary, in English
Fifty-four type 2 diabetic patients with neuroischemic foot ulcers were randomised to treatment with 5000 IU of dalteparin, (n = 28), or physiological saline, (n = 26), once daily until ulcer healing or for a maximum of 6 months. Thirty-three patients had normo-, 15 micro-, and 6 macroalbuminuria. The urinary levels of IgM and IgG(2) were elevated in 47 and 50 patients, respectively. Elevated urinary levels of IgM and IgG(2) indicate decreased glomerular size selectivity. Urine IgM levels were associated with IGF-1/IGFBP-1 and IGFBP-1 levels. Dalteparin treatment increased urinary levels of glycosaminoglycans (P < 0.001) and serum IGFBP-1 (P < 0.05) while no significant effects were seen in any of the other studied parameters. In conclusion, dalteparin therapy in patients with type 2 diabetes had no effects on urinary levels of albumin, IgM, or IgG(2) despite significantly increased glycosaminoglycans in urine. Elevated urinary levels of IgM and IgG(2) might be more sensitive markers of renal disease than albuminuria in patients with type 2 diabetes and antihypertensive therapy.
Department/s
Publishing year
2012
Language
English
Publication/Series
Biochemistry Research International
Volume
2012
Full text
- Available as PDF - 548 kB
- Download statistics
Links
Document type
Journal article
Publisher
Hindawi Limited
Topic
- Biochemistry and Molecular Biology
Status
Published
Research group
- Genomics, Diabetes and Endocrinology
ISBN/ISSN/Other
- ISSN: 2090-2247